Weekly cisplatin chemoradiation (with pembrolizumab for high-risk disease)
Checked 2026-09-09
Locally advanced cervical cancer (FIGO IB2-IVA); pembrolizumab for FIGO 2014 III-IVA or node-positive
One cycle
weekly × 5-6 · about 5 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Cisplatin Cytotoxic chemotherapy (platinum) | 40 mg/m² (maximum 70 mg) | IV | D1 | |
Pembrolizumab (KEYNOTE-A18) Monoclonal antibody (anti-PD-1) | 200 mg every 3 weeks × 5, then 400 mg every 6 weeks × 15 | IV | D1 | every third week |
Radiotherapy | 45-50.4 Gy external beam plus brachytherapy | Radiotherapy | D1-5 |
Cycles
5-6 weekly doses with external beam and brachytherapy
7-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- INTERLACE: 6 weeks of induction carboplatin AUC 2 + paclitaxel 80 mg/m² before chemoradiation improved OS.
Used in
Products
Source
Rose, NEJM 1999; NCCN Cervical Cancer
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Topotecan
Relapsed SCLC; platinum-resistant ovarian or cervical cancer
every 21 days
Carboplatin + paclitaxel
Ovarian cancer adjuvant or neoadjuvant (6 cycles); advanced endometrial cancer with pembrolizumab or dostarlimab; NSCLC
every 21 days × 6
Pembrolizumab + platinum + paclitaxel ± bevacizumab (cervical)
Persistent, recurrent or metastatic cervical cancer, PD-L1 CPS 1 or above
every 21 days
Pembrolizumab monotherapy
Adjuvant melanoma stage IIB-IV (1 year); PD-L1 TPS 50% or above NSCLC; MSI-high tumours; recurrent head and neck (CPS 1 or above)
every 21 days
High-dose cisplatin chemoradiation
Locally advanced head and neck squamous cell carcinoma, definitive or postoperative (positive margins or extranodal extension)
every 21 days × 3
TPF induction
Locally advanced head and neck cancer where induction is chosen (larynx preservation, bulky nodes)
every 21 days × 3-4
Pembrolizumab + platinum + fluorouracil
Recurrent or metastatic head and neck squamous cell carcinoma, first line
every 21 days